Is REGENERON PHARMACEUTICALS (NASDAQ:REGN) suited for quality investing?

In this article we will dive into REGENERON PHARMACEUTICALS (NASDAQ:REGN) as a possible candidate for quality investing. Investors should always do their own research, but we noticed REGENERON PHARMACEUTICALS showing up in our Caviar Cruise quality screen, which makes it worth to investigate a bit more.

What matters for quality investors.

• Over the past 5 years, REGENERON PHARMACEUTICALS has experienced impressive revenue growth, with 15.7% increase. This demonstrates the company's ability to effectively expand its top line and suggests a positive outlook for future revenue generation.
• The ROIC excluding cash and goodwill of REGENERON PHARMACEUTICALS stands at 21.99%, reflecting the company's strong financial management and profitability. This metric underscores its ability to generate favorable returns on the capital invested in its core operations.
• REGENERON PHARMACEUTICALS maintains a healthy Debt/Free Cash Flow Ratio of 0.9, indicating a strong financial position and prudent debt management. This ratio suggests the company has sufficient free cash flow to cover its debt obligations and highlights its ability to generate cash from operations.
• REGENERON PHARMACEUTICALS demonstrates consistent Profit Quality over the past 5 years, with a strong 76.98%. This indicates the company's ability to generate sustainable and reliable profits, showcasing its long-term profitability and financial stability.
• The 5-year EBIT growth of REGENERON PHARMACEUTICALS has been remarkable, with 19.15% increase. This demonstrates the company's ability to improve its operational efficiency and indicates its competitiveness within the market.
• The EBIT 5-year growth of REGENERON PHARMACEUTICALS has outpaced its Revenue 5-year growth, reflecting the company's focus on optimizing its profitability and generating sustainable earnings. This trend underscores its strong financial management.

Fundamental analysis of NASDAQ:REGN

Every day, ChartMill assigns a Fundamental Rating to each stock, providing a score ranging from 0 to 10. This rating is determined by evaluating various fundamental indicators and properties.

We assign a fundamental rating of 7 out of 10 to REGN. REGN was compared to 616 industry peers in the Biotechnology industry. Both the health and profitability get an excellent rating, making REGN a very profitable company, without any liquidiy or solvency issues. REGN has a decent growth rate and is not valued too expensively.

Our latest full fundamental report of REGN contains the most current fundamental analsysis.

More ideas for quality investing can be found on ChartMill in our Caviar Cruise screen.

Keep in mind

Important Note: The content of this article is not intended as trading advice. It is essential to perform your own analysis and exercise caution when making trading decisions. The article presents observations created by automated analysis but does not guarantee any trading or investment outcomes. Always trade responsibly and make independent judgments.